A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Participants.
Latest Information Update: 26 Mar 2026
At a glance
- Drugs SV 003 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Shanghai Synvida Biotechnology
Most Recent Events
- 26 Mar 2026 New trial record